---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-26-000047"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2026-08-04T12:02:40+00:00"
generated_at: "2026-08-04T12:05:04.276130+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exagen Q2 2026: record revenue $19.9M (+16% YoY), net loss narrowed, guidance raised

## Summary
- Revenue $19.9M, up 16% YoY; net loss $3.2M vs $4.4M in Q2 2025, improved 28%.
- Adjusted EBITDA loss narrowed to $0.1M from $1.7M; operating loss $1.7M vs $2.6M.
- AVISE CTD test volume +11% YoY; trailing 12-month ASP $446, up $18 (+4%).
- Full-year 2026 revenue guidance raised to $72-75M from prior $70-73M.
- Cash $24.6M; published study showing AVISE Lupus identified ~25% of SLE patients missed by conventional markers.

## SEC filing metadata
- accession: 0001274737-26-000047
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2026-08-04T12:02:40+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/0001274737-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/exdx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-26-000047
- JSON: https://secwatch.observer/filing/0001274737-26-000047.json
- Plain text: https://secwatch.observer/filing/0001274737-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.